This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
This is a web analytics service.
Processing company
  • Google Ireland Limited
  • Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
  • Facebook Ireland Limited
  • 4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
  • advertising
  • Marketing
  • Retargeting
  • Analyse
  • Tracking
Technologies Used
  • Cookies
Data Attributes
  • Pixel specific data
  • Http-Header
  • Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • Facebook user ID
  • Browser information
  • Usage data
  • Geräteinformationen
  • Non-sensitive custom data
  • Referrer URL
  • Pixel ID
  • Location information
  • Pixel specific data
  • User behaviour
  • Ads viewed
  • Interactions with advertisement, services, and products
  • Marketing information
  • Content viewed
  • IP address
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Facebook Inc.
This is a web analytics service.
Processing company
  • Zoom Analytics Ltd.
  • Petah Tikva, Israel
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
Medicines for Three Continents from the Heart of Mačva
09. November 2016.
Hemofarm’s Šabac-based Plant, an important chain in the system of the regional pharmaceutical leader, has celebrated four decades of successful business operations. Found back in 1976, over the course of 40 years of its existence, this factory has passed a dynamic and interesting development path. From a modest plant for production of syrups, creams and five types of infusion solutions, it first became a part of Vršac-based Hemofarm, and then also a part of German STADA Group, which enabled it an access to international markets in 38 countries worldwide, as well as market distinctiveness.

A cocktail reception, organized for employees and media representatives, was opened by the host, Director of the Šabac-based Plant Dragan Tošić.

’Hemofarm Šabac produces, inter alia, medicines transferred by STADA, and it is the only factory that produces pellets – a very complex technology of pellet coating with suspension multilayers, and within Hemofarm, it specializes in capsule production. It is our manufacturing specificity within these two powerful regional and global pharmaceutical groups, simultaneously representing our point of integration and awareness that without Hemofarm, and particularly without STADA, we wouldn’t hold such a market position’, Dragan Tošić said.

Hemofarm has also marked a decade of business operations within STADA Group this year, and it has also been a STADA’s hub for Southeast European markets as of this year. The path of Hemofarm to becoming a national business symbol has also been paved by the decision of the top management to invest in employees to the same extent as in production.

‘I am heading a company that has more than 2700 people and it is not just an empty phrase when I say that all of us together are a part of a large family. Everyone in this family knows their responsibilities and each one of us aspires to the same goal – to produce quality and affordable medicines and to keep the position of one of the major global generic manufacturers under the auspices of STADA’, Ronald Seeliger, CEO of Hemofarm and Vice President of STADA, said.

Over the course of 40 years of its business operations in Šabac, Hemofarm has become not only a partner to the local community, but also its inseparable part. Hemofarm has proven that it abides by corporate social responsibility and the principles of sustainable development, among other things, by several million worth investment in the waste water treatment facility or by investing into forest-planting of Šabac, in which segment it exercises an exceptional cooperation with local self-government.

’Apart from being one of the business pillars of the town and a symbol of stability, Hemofarm’s Šabac-based Plant is also a good neighbor, partner and member of the local community. We have jointly initiated numerous projects, and I’m looking forward to good cooperation also in the years ahead. The town Šabac is capable of responding to all requirements of businessmen, and it is therefore the best place for investing in Serbia’, Mayor of Šabac Nebojša Zelenović pointed out in his felicitation speech on the occasion of the anniversary.

Hemofarm in Šabac has 379 employees in Solid, Semi-Solid and Liquid Forms Plants, and the most state-of-the-art Disinfectants and Medical Solutions Plant. A record-breaking output of 55 million packs is expected to be achieved this year, as well as the completion of the annual investment cycle worth almost five million euros. The Plant meets the strictest global production and supply standards. Medicines from Šabac travel to the markets of the region, the European Union, and even far away to Russia, Ukraine, Armenia and numerous Asian and African countries. A recognition was received from the World Bank last year according to which the Šabac-based Plant is among 10 percent of the best factories in terms of energy efficiency.